Chronic Myeloid Leukemia Treatment in India – Best Hospitals & Doctors

Learn about Chronic Myeloid Leukemia Treatment in India — how it works, who it is for, recovery timelines, and what to expect before and after surgery. Compare hospitals and doctors experienced in Chronic Myeloid Leukemia and request assistance for cost estimates or appointments.

Partner Hospitals

0 partner in India for this surgery

Specialist Doctors

2 Surgeons linked to this surgery

Treatment Cost

Approx INR 10 Thousand – 300 Thousand

About Chronic Myeloid Leukemia

Chronic Myeloid Leukemia (CML) is a type of blood and bone marrow cancer characterized by the uncontrolled growth of myeloid cells. A Hemato Oncologist, a specialist in blood cancers, manages this condition through a targeted, long-term treatment strategy rather than a single procedure. The cornerstone of modern CML treatment is Tyrosine Kinase Inhibitor (TKI) therapy, which uses oral medications to block the abnormal BCR-ABL protein driving the cancer. Treatment is highly personalized, involving regular monitoring of blood counts and molecular response through PCR tests. The goal is to achieve and maintain a deep molecular response, potentially allowing for treatment-free remission in some patients. For those who do not respond adequately to TKIs, or in advanced phases, procedures like stem cell transplantation may be considered. Ongoing care focuses on managing side effects and ensuring optimal quality of life.

Key Highlights

Highly Targeted Therapy: TKIs specifically attack the BCR-ABL protein, sparing most healthy cells.Oral Medication: Primary treatment is often in convenient pill form, allowing for outpatient management.Transformed Prognosis: Has changed CML from a fatal disease to a manageable chronic condition for most patients.listrongPersonalized Treatment Plans:/strong Therapy is tailored based on individual risk scores, response, and tolerance./lilistrongGoal of Treatment-Free Remission:/strong With deep molecular response, some patients may safely discontinue medication under close supervision./li/ul

Who is this surgery for?

Diagnosis of Chronic Phase, Accelerated Phase, or Blast Phase Chronic Myeloid Leukemia confirmed by blood tests, bone marrow biopsy, and cytogenetic/molecular studies (Philadelphia chromosome, BCR-ABL gene).
Presence of symptoms like fatigue, unexplained weight loss, night sweats, abdominal fullness (from spleen enlargement), or easy bruising/bleeding.
Incidental finding of a high white blood cell count, especially with immature cells (myelocytes, promyelocytes), on a routine blood test.
Failure or intolerance to first-line Tyrosine Kinase Inhibitor (TKI) therapy.
Disease progression or relapse after initial treatment.

How to prepare

Comprehensive Diagnosis: Undergo complete blood count (CBC), bone marrow aspiration and biopsy, and cytogenetic/FISH testing for the Philadelphia chromosome and PCR for BCR-ABL quantification.
Baseline Assessments: Complete cardiac evaluation (ECG, echocardiogram), liver and kidney function tests, and screening for other infections.
Consultation: Detailed discussion with the Hemato Oncologist about treatment options (e.g., Imatinib, Dasatinib, Nilotinib), goals, potential side effects, and monitoring schedule.
Lifestyle & Support: Review all current medications, plan for potential side effect management, and establish a strong support system.
Financial & Logistical Planning: Understand insurance coverage for long-term medication and arrange for regular follow-up and blood test appointments.

Risks & possible complications

Medication Side Effects: TKIs can cause fluid retention, muscle cramps, rash, fatigue, nausea, and low blood counts.
Organ Toxicity: Potential for liver enzyme elevation, heart complications (QT prolongation), or lung issues (pleural effusion with some TKIs).
Treatment Resistance: Development of mutations in the BCR-ABL gene that make the cancer resistant to specific TKIs.
Infections: Increased risk due to low white blood cell counts (neutropenia).
Bleeding/Bruising: Risk associated with low platelet counts (thrombocytopenia).
Long-Term Effects: Possible impact on bone health, kidney function, and cardiovascular health with prolonged TKI use.
Stem Cell Transplant Risks: If required, includes graft-versus-host disease, severe infections, and organ damage.

Recovery & hospital stay

Ongoing Monitoring: Regular blood tests (every 1-3 months initially) and periodic PCR tests to measure molecular response are crucial for life.
Side Effect Management: Proactively managing medication side effects with supportive care, dose adjustments, or switching TKIs as advised by the oncologist.
Lifestyle Adaptations: Maintaining a balanced diet, engaging in gentle exercise as tolerated, and avoiding infections through good hygiene.
Psychological Support: Coping with a chronic cancer diagnosis may require counseling or support groups.
Achieving Milestones: The recovery journey is measured by achieving hematologic, cytogenetic, and molecular response milestones over months and years.
Treatment-Free Remission: For eligible patients with a sustained deep molecular response, a carefully monitored attempt to stop medication may be considered.

Typical hospital stay: 0 days (primarily outpatient) or 4-6 weeks (if stem cell transplant required)
Expected recovery time: Lifelong management; initial stabilization in 3-6 months

Frequently Asked Questions

If you are considering chronic myeloid leukemia in India, these questions and answers can help you make a confident, informed decision.

＋ − Which hospitals are best for chronic myeloid leukemia in India?

Top-rated hospitals in India with hemato oncology departments and experienced surgeons are ideal for this procedure. Use MediFyr to compare facilities, reviews, and doctor profiles before you decide.

＋ − How do I choose the right doctor for chronic myeloid leukemia?

Look at the doctor’s years of experience, hospital association, patient reviews, and how often they perform chronic myeloid leukemia. MediFyr helps you compare hemato oncologists and book consultations online.

＋ − What factors affect the cost of chronic myeloid leukemia?

The overall cost depends on hospital category, surgeon’s experience, room type, implant or device used (if any), length of stay, tests, and post-operative care. Our team can help you get cost estimates from multiple hospitals before you decide.

Get assistance for Chronic Myeloid Leukemia

Share a few details and our team will help you compare hospitals, understand costs, and schedule a consultation with the right specialist.

Real People Helping Real Patients!
Get Assistance.

INR 10 Thousand – 300 Thousand
Typical stay: 0 days (primarily outpatient) or 4-6 weeks (if stem cell transplant required)
Recovery: ~Lifelong management; initial stabilization in 3-6 months

Procedure cost in other countries

Here is an overview of how the estimated cost, hospital stay, and recovery time for chronic myeloid leukemia compare across other countries where we have data.

Country	Estimated cost range	Typical stay	Recovery time	View details
India	INR 10 Thousand – 300 Thousand	0 days (primarily outpatient) or 4-6 weeks (if stem cell transplant required)	~ Lifelong management; initial stabilization in 3-6 months	Know More
Turkey	TRY 35 Thousand – 1.05 Million	0 days (primarily outpatient) or 4-6 weeks (if stem cell transplant required)	~ Lifelong management; initial stabilization in 3-6 months	Know More

PATIENT REVIEW

Ayaan Gupta, a 42-year-old software engineer...

Ayaan Gupta, a 42-year-old software engineer and father of two young children, had always been healthy. Over several months, he noticed a persistent fatigue that coffee couldn't fix, night sweats that soaked his sheets, and a feeling of fullness in his left side. He initially blamed his stressful job, but a routine check-up revealed a dramatically elevated white blood cell count. A subsequent bone marrow biopsy confirmed Chronic Myeloid Leukemia (CML). His Hemato-Oncologist, Dr. Sharma, explained that Ayaan's CML was driven by the Philadelphia chromosome and recommended starting a targeted therapy called a Tyrosine Kinase Inhibitor (TKI), specifically Imatinib. The first few weeks were rough; Ayaan experienced significant muscle cramps, fatigue, and a skin rash. He felt scared and guilty, worrying about his family's future. With dose adjustments and supportive medications, the side effects became manageable. After three months, his blood counts normalized, and a PCR test showed a major molecular response. Ayaan's emotional journey was one of initial terror and vulnerability, transforming into cautious hope. He learned to manage his condition as a chronic illness, not a death sentence. He returned to work full-time, coaches his son's soccer team on weekends, and feels profound gratitude for the science that gave him his life back, though he lives with the constant awareness of needing daily medication and regular monitoring.